Press Releases

Date Title and Summary Additional Formats
Toggle Summary Marinus Pharmaceuticals to Present at the Stifel Healthcare Conference
RADNOR, Pa., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Christopher M. Cashman, Chairman and Chief Executive Officer of Marinus, will...
View HTML
Toggle Summary Marinus Pharmaceuticals, Inc. to Present at the 21st Annual BioCentury Newsmakers Conference on Friday, September 26, 2014
NEW HAVEN, Conn., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Edward F. Smith, Vice President and Chief Financial Officer of Marinus will...
View HTML
Toggle Summary Marinus Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option in Public Offering of Common Stock
NEW HAVEN, Conn., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that the underwriters of its previously announced public offering of common stock...
View HTML
Toggle Summary Marinus Pharmaceuticals, Inc. to Ring the Opening Bell of the NASDAQ Stock Market
NEW HAVEN, Conn., Aug. 25, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that in celebration of its recently completed initial public offering and NASDAQ...
View HTML
Toggle Summary Marinus Pharmaceuticals, Inc. Enters Into Use Agreement With CyDex Pharmaceuticals, Inc. for Use of Captisol(R) for Ganaxolone IV
NEW HAVEN, Conn., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that it has entered into an agreement with CyDex Pharmaceuticals, Inc., a wholly...
View HTML
Toggle Summary Marinus Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
NEW HAVEN, Conn., July 31, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced the pricing of its initial public offering of 5,625,000 shares of its common stock...
View HTML
Toggle Summary Marinus Pharmaceuticals Bolsters Its Board of Directors and Executive Management
Elects Two Life Sciences Veterans, Enrique J. Carrazana, M.D. and Jay P. Shepard, to Its Board of Directors; Appoints Edward F. Smith as Chief Financial Officer ...
View HTML
Toggle Summary RusnanoMedInvest and Domain Associates Invest In Neurology Company Marinus Pharmaceuticals
RusnanoMedInvest and Domain Associates Invest In Neurology Company Marinus Pharmaceuticals BRANFORD, Conn. , Jan. 7, 2013 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano...
View HTML
Toggle Summary Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome NEW HAVEN, Conn. , April 13, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the...
View HTML
Toggle Summary Marinus Pharmaceuticals Issued Patent for Ganaxolone
Marinus Pharmaceuticals Issued Patent for Ganaxolone NEW HAVEN, Conn. , April 7, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the...
View HTML